Israel - englanti - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - englanti - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - englanti - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Euroopan unioni - englanti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - lenalidomide - multiple myeloma; lymphoma, mantle-cell; myelodysplastic syndromes - immunosuppressants - multiple myelomarevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.myelodysplastic syndromesrevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.mantle cell lymphomarevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

teva b.v. - lenalidomide - capsule, hard - 10 milligram(s) - other immunosuppressants; lenalidomide

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

teva b.v. - lenalidomide - capsule, hard - 15 milligram(s) - other immunosuppressants; lenalidomide

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

teva b.v. - lenalidomide hydrochloride hydrate - capsule, hard - 2.5 milligram(s) - other immunosuppressants; lenalidomide

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

teva b.v. - lenalidomide - capsule, hard - 20 milligram(s) - other immunosuppressants; lenalidomide

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

teva b.v. - lenalidomide - capsule, hard - 25 milligram(s) - other immunosuppressants; lenalidomide

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

teva b.v. - lenalidomide - capsule, hard - 5 milligram(s) - other immunosuppressants; lenalidomide